Sandbox ID Cardiovascular: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
mNo edit summary
mNo edit summary
Line 1: Line 1:
* Endocarditis<ref>{{Cite journal| doi = 10.1161/CIRCULATIONAHA.105.165564| issn = 1524-4539| volume = 111| issue = 23| pages = –394-434| last1 = Baddour| first1 = Larry M.| last2 = Wilson| first2 = Walter R.| last3 = Bayer| first3 = Arnold S.| last4 = Fowler| first4 = Vance G.| last5 = Bolger| first5 = Ann F.| last6 = Levison| first6 = Matthew E.| last7 = Ferrieri| first7 = Patricia| last8 = Gerber| first8 = Michael A.| last9 = Tani| first9 = Lloyd Y.| last10 = Gewitz| first10 = Michael H.| last11 = Tong| first11 = David C.| last12 = Steckelberg| first12 = James M.| last13 = Baltimore| first13 = Robert S.| last14 = Shulman| first14 = Stanford T.| last15 = Burns| first15 = Jane C.| last16 = Falace| first16 = Donald A.| last17 = Newburger| first17 = Jane W.| last18 = Pallasch| first18 = Thomas J.| last19 = Takahashi| first19 = Masato| last20 = Taubert| first20 = Kathryn A.| last21 = Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease| last22 = Council on Cardiovascular Disease in the Young| last23 = Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia| last24 = American Heart Association| last25 = Infectious Diseases Society of America| title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America| journal = Circulation| date = 2005-06-14| pmid = 15956145}}</ref>
* Endocarditis<ref>{{Cite journal| doi = 10.1161/CIRCULATIONAHA.105.165564| issn = 1524-4539| volume = 111| issue = 23| pages = –394-434| last1 = Baddour| first1 = Larry M.| last2 = Wilson| first2 = Walter R.| last3 = Bayer| first3 = Arnold S.| last4 = Fowler| first4 = Vance G.| last5 = Bolger| first5 = Ann F.| last6 = Levison| first6 = Matthew E.| last7 = Ferrieri| first7 = Patricia| last8 = Gerber| first8 = Michael A.| last9 = Tani| first9 = Lloyd Y.| last10 = Gewitz| first10 = Michael H.| last11 = Tong| first11 = David C.| last12 = Steckelberg| first12 = James M.| last13 = Baltimore| first13 = Robert S.| last14 = Shulman| first14 = Stanford T.| last15 = Burns| first15 = Jane C.| last16 = Falace| first16 = Donald A.| last17 = Newburger| first17 = Jane W.| last18 = Pallasch| first18 = Thomas J.| last19 = Takahashi| first19 = Masato| last20 = Taubert| first20 = Kathryn A.| last21 = Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease| last22 = Council on Cardiovascular Disease in the Young| last23 = Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia| last24 = American Heart Association| last25 = Infectious Diseases Society of America| title = Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America| journal = Circulation| date = 2005-06-14| pmid = 15956145}}</ref>
:* Culture-negative endocarditis:
::* {{Regimen|Native_valve_endocarditis| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
::* {{Regimen|Prosthetic_valve_endocarditis| – Preferred regimen: 123 <br> – Alternative regimen: 123}}
:* Viridans Group Streptococci and Streptococcus bovis  
:* Viridans Group Streptococci and Streptococcus bovis  
::* Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis
::* Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis

Revision as of 06:26, 23 May 2015

  • Endocarditis[1]
  • Viridans Group Streptococci and Streptococcus bovis
  • Highly Penicillin-Susceptible Viridans Group Streptococci and Streptococcus bovis
  • Preferred regimen: Penicillin G 12–18 million U/24 h IV either continuously or in 4 or 6 equally divided doses for 4 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 4 weeks
  • Alternative regimen (1): (Penicillin G 12–18 million U/24 h IV either continuously or in 6 equally divided doses for 2 weeks OR Ceftriaxone 2 g/24h IV/IM in 1 dose for 2 weeks) PLUS Gentamicin 3 mg/kg per 24h IV/IM in 1 dose for 2 weeks
  • Alternative regimen (2): Vancomycin 30 mg/kg per 24 h IV in 2 equally divided doses not to exceed 2 g/24 h for 4 weeks
  • Pediatric dose: Penicillin G 200,000 U/kg per 24 h IV in 4–6 equally divided doses; Ceftriaxone 100 mg/kg per 24 h IV/IM in 1 dose; Gentamicin 3 mg/kg per 24 h IV/IM in 1 dose or 3 equally divided doses; Vancomycin 40 mg/kg per 24 h IV in 2–3 equally divided doses
  • Relatively Penicillin-Resistant Viridans Group Streptococci and Streptococcus bovis
  • Preferred regimen:
  • Alternative regimen:


  • Prophylactic therapy
  • Dental prophylaxis
  • Lyme carditis
  • Mycotic aneurysm
  • Implantable electronic device infections
  • Pericarditis
  • Bacterial pericarditis
  • Histoplasmosis
  • Extrapulmonary tuberculosis
  • Rheumatic fever
  • Cavernous sinus thrombosis
  • Intravenous line infections
  • Intravenous line infections, non-tunneled
  • Intravenous line infections, tunneled
  • Septic pelvic vein thrombophlebitis
  • Suppurative phlebitis
  • Ventricular-assist device infections

References

  1. ↑ Baddour, Larry M.; Wilson, Walter R.; Bayer, Arnold S.; Fowler, Vance G.; Bolger, Ann F.; Levison, Matthew E.; Ferrieri, Patricia; Gerber, Michael A.; Tani, Lloyd Y.; Gewitz, Michael H.; Tong, David C.; Steckelberg, James M.; Baltimore, Robert S.; Shulman, Stanford T.; Burns, Jane C.; Falace, Donald A.; Newburger, Jane W.; Pallasch, Thomas J.; Takahashi, Masato; Taubert, Kathryn A.; Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease; Council on Cardiovascular Disease in the Young; Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia; American Heart Association; Infectious Diseases Society of America (2005-06-14). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): –394-434. doi:10.1161/CIRCULATIONAHA.105.165564. ISSN 1524-4539. PMID 15956145.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox_ID_Cardiovascular&oldid=1101389"